Company intelligence / Profile preview

Hemoglobin Oxygen Therapeutics

Souderton, Pennsylvania, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Hemopure® (hemoglobin glutamer 250 bovine) is approved in South Africa and Russia for human use as an alternative to allogeneic blood transfusion, with Oxyglobin® approved for veterinary use in the US and EU. Clinical studies show Hemopure increases tissue and organ oxygenation and may have utility in organ preservation for transplantation, but broad FDA approval for human use remains pending. Recent preclinical data indicate Hemopure restored organ function after severe ischemia in animal studies[6][9][5].

Therapeutic areas: CardiovascularHematology
Modalities: BiologicRecombinant proteinBlood component therapyMedical device
Industry: Biotech

Drug pipeline

1 asset

hemoglobin glutamer-250

Beyond the preview

Go deeper on Hemoglobin Oxygen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemoglobin Oxygen Therapeutics.

Explore the full profile